StrokeNCT07237633
Evaluating the Feasibility of a Piezoelectric Smart Sensor as an Aid to Help Clinicians Screen for the Development of Pneumonia in an At-risk Population
A study testing Piezoelectric sensor in people with Stroke and End Stage Renal Failure on Dialysis, run by National University Hospital, Singapore at 1 site in Singapore.
Trial summary
This proposed research aims to evaluate the feasibility of the piezoelectric sensor as an aid to help clinicians screen for the development of pneumonia in an at-risk population. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Stroke, End Stage Renal Failure on Dialysis
- What is being tested?
- Piezoelectric sensor
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteSingapore
- Study dates
- 18 Jan 2023to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 21 years and above
- Acute stroke patients (i.e. MRI or CT brain findings consistent with diagnosis) or ESRF patients on HD who are mentally competent and cognitively fit to provide consent.
Who cannot join
- Individuals who are unable to give informed consent
- Individuals with active dermatological conditions
Trial locations and contacts
1 site in 1 country.
About this study
This proposed research aims to evaluate the feasibility of the piezoelectric sensor as an aid to help clinicians screen for the development of pneumonia in an at-risk population.
Read the detailed description
This is a proof of concept study to demonstrate that the piezoelectric sensor can be used as an aid to help clinicians screen for the development of pneumonia in at-risk populations (i.e. hospitalized patients with acute stroke and COVID-19 patients). The findings from this study can be extrapolated to the other community settings (e.g. nursing homes, dormitories) where access to healthcare is more limited. The decision to site this study in an acute hospital or community care facility (CTF) is largely pragmatic - easier access to patients; investigations (e.g. chest x-ray, blood tests) and treatment are more readily available for patients without any need for their transfer.
As this is a proof of concept study, the project number of subject required was not based on statistical power calculation. A total of 70 subjects will be recruited. The sample size of 30 participants is a pragmatic decision based on feasibility and is typical for a proof of concept study of this nature.
A total of 70 subjects, including those with acute stroke (with MRI or CT brain evidence of acute stroke) at NUH, those with ESRF (End Stage Renal Failure) on HD (hemodialysis) at NUH, The piezoelectric sensor will be applied to the posterior chest wall (6-point) of the subject at one time point daily (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded. CXR (Chest X-Ray) will be performed if the clinician and/or piezoelectric sensor detects abnormal chest sounds that is suggestive of pneumonia or fluid overload.
The piezoelectric sensor will be applied to the skin of the subject at the 6 points on the posterior chest wall for 30 seconds at each position. The piezoelectric sensors will be carefully sterilized with alcohol swaps before and after each placement. The program algorithm will then determine the type of lung sound recorded by the piezoelectric sensors.
CXR will be performed to determine the presence of pneumonia or fluid overload if the clinician and/or piezoelectric smart sensor detects abnormal lung sounds. CXR may not be performed if it is not required based on primary team's clinical assessment.
The piezoelectric sensor will be applied to the posterior chest wall of the subject at one time point daily (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded, until pneumonia or fluid overload is detected and confirmed by CXR or the subject is discharged, whichever is earlier. In the event that the subject declines to have the piezoelectric sensor placed every day, a minimum of 50% of compliance rate is required.
If the piezoelectric sensor detects abnormal lung sounds while CXR is normal, the sensor will continue to be placed on the subject daily until CXR confirms pneumonia or fluid overload or the subject is discharged, whichever is earlier.
A standard posterior to anterior view CXR will be obtained if the piezoelectric sensor detects abnormal lung sounds and the CXR will be interpreted using a standardized approach.
- Conditions
- Stroke, End Stage Renal Failure on Dialysis
- Being tested
- Piezoelectric sensor
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Piezoelectric sensorDevice
The piezoelectric sensor will be applied to the posterior chest wall of all recruited subjects once daily at one time point (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded, until pneumonia or fluid overload is detected and confirmed by CXR or the subject is discharged, whichever is earlier.
| Study group | Role | What they receive |
|---|---|---|
| Piezoelectric sensor | Experimental | The piezoelectric sensor will be applied to the posterior chest wall of all recruited subjects once daily at one time point (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded, until pneumonia or fluid overload is detected and confirmed by CXR or the subject is discharged, whichever is earlier. Receives: Device: Piezoelectric sensor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of pneumonia
The piezoelectric sensor detects abnormal chest sounds that is suggestive of pneumonia or fluid overload and is confirmed by CXR.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2025
- Study start18 Jan 2023
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by National University Hospital, SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- National University Hospital, Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- National University of Singapore
- Responsible party
- Sponsor
- Investigators
- Hiang Ping CHAN, MBBS, Principal investigator, National University Hospital, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07237633
- Sponsor's protocol ID
- 2021/01082
- Status last verified
- Jul 2026
- First submitted
- 16 Nov 2025
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Feasibility of a Piezoelectric Smart Sensor as an Aid to Help Clinicians Screen for the Development of Pneumonia in an At-risk Population
- ClinicalTrials.gov ID
- NCT07237633
- Acronym / sponsor ID
- 2021/01082
- Conditions
- Stroke, End Stage Renal Failure on Dialysis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- National University Hospital, SingaporeUniversity, hospital or other
- Collaborators
- National University of Singapore
- Study start
- 18 Jan 2023 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 20 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This proposed research aims to evaluate the feasibility of the piezoelectric sensor as an aid to help clinicians screen for the development of pneumonia in an at-risk population.
Detailed description
This is a proof of concept study to demonstrate that the piezoelectric sensor can be used as an aid to help clinicians screen for the development of pneumonia in at-risk populations (i.e. hospitalized patients with acute stroke and COVID-19 patients). The findings from this study can be extrapolated to the other community settings (e.g. nursing homes, dormitories) where access to healthcare is more limited. The decision to site this study in an acute hospital or community care facility (CTF) is largely pragmatic - easier access to patients; investigations (e.g. chest x-ray, blood tests) and treatment are more readily available for patients without any need for their transfer.
As this is a proof of concept study, the project number of subject required was not based on statistical power calculation. A total of 70 subjects will be recruited. The sample size of 30 participants is a pragmatic decision based on feasibility and is typical for a proof of concept study of this nature.
A total of 70 subjects, including those with acute stroke (with MRI or CT brain evidence of acute stroke) at NUH, those with ESRF (End Stage Renal Failure) on HD (hemodialysis) at NUH, The piezoelectric sensor will be applied to the posterior chest wall (6-point) of the subject at one time point daily (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded. CXR (Chest X-Ray) will be performed if the clinician and/or piezoelectric sensor detects abnormal chest sounds that is suggestive of pneumonia or fluid overload.
The piezoelectric sensor will be applied to the skin of the subject at the 6 points on the posterior chest wall for 30 seconds at each position. The piezoelectric sensors will be carefully sterilized with alcohol swaps before and after each placement. The program algorithm will then determine the type of lung sound recorded by the piezoelectric sensors.
CXR will be performed to determine the presence of pneumonia or fluid overload if the clinician and/or piezoelectric smart sensor detects abnormal lung sounds. CXR may not be performed if it is not required based on primary team's clinical assessment.
The piezoelectric sensor will be applied to the posterior chest wall of the subject at one time point daily (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded, until pneumonia or fluid overload is detected and confirmed by CXR or the subject is discharged, whichever is earlier. In the event that the subject declines to have the piezoelectric sensor placed every day, a minimum of 50% of compliance rate is required.
If the piezoelectric sensor detects abnormal lung sounds while CXR is normal, the sensor will continue to be placed on the subject daily until CXR confirms pneumonia or fluid overload or the subject is discharged, whichever is earlier.
A standard posterior to anterior view CXR will be obtained if the piezoelectric sensor detects abnormal lung sounds and the CXR will be interpreted using a standardized approach.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Piezoelectric sensor | Experimental | Device: Piezoelectric sensorThe piezoelectric sensor will be applied to the posterior chest wall of all recruited subjects once daily at one time point (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded, until pneumonia or fluid overload is detected and confirmed by CXR or the subject is discharged, whichever is earlier. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Aged 21 years and above
- Acute stroke patients (i.e. MRI or CT brain findings consistent with diagnosis) or ESRF patients on HD who are mentally competent and cognitively fit to provide consent.
Key exclusion criteria (2 listed)
- Individuals who are unable to give informed consent
- Individuals with active dermatological conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Piezoelectric sensorThe piezoelectric sensor will be applied to the posterior chest wall of all recruited subjects once daily at one time point (excluding weekends, public holidays and discharge day) up to 2 weeks whilst he/she is warded, until pneumonia or fluid overload is detected and confirmed by CXR or the subject is discharged, whichever is earlier. | Device | Piezoelectric sensor |
Primary outcome
Detection of pneumonia
Time frame: 3 years
The piezoelectric sensor detects abnormal chest sounds that is suggestive of pneumonia or fluid overload and is confirmed by CXR.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hiang Ping CHAN, MBBS principal investigator
National University Hospital, Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Piezoelectric sensor in people with Stroke and End Stage Renal Failure on Dialysis, run by National University Hospital, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of pneumonia (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.